Aspirin use prior to intracerebral hemorrhage was associated with a significantly higher rate of lobar hematoma compared to nonusers (32.8% vs 10.3%, p=0.002).
Case-Control (n=174)
No
Absolute Event Rate: 32.8% vs 10.3%
p-value: p=0.002
OBJECTIVE: To identify the clinical and radiologic features of intracerebral hemorrhage (ICH) in aspirin users. BACKGROUND: Although the benefits of aspirin outweigh its hemorrhagic risks for patients at high risk of vascular diseases, prolonged use of aspirin is associated with an increased risk of ICH. METHODS: The authors enrolled consecutive patients with acute stroke who were admitted to a regional hospital from 1993 to 1998 into a stroke registry. From this registry, they identified all stroke patients who had ICH confirmed by CT scan and then selected those taking regular aspirin before ICH as the study group. For each study patient, they selected the immediate next two patients with ICH but not taking aspirin as controls. RESULTS: The authors identified 58 aspirin users and 1193 nonusers among all patients hospitalized for ICH. From the group of nonusers, they selected 116 patients as controls. The locations of the hematoma were different (p = 0.002), with more lobar hematoma in the aspirin group (32.8%) than in the control group (10.3%). Prior cerebrovascular disease was the reason for taking aspirin in 37 (64%) patients but five patients had prior ICH. CONCLUSIONS: The propensity for lobar hematoma in aspirin-associated ICH suggests its pathology may be somewhat different from spontaneous ICH among nonaspirin users. Further research to examine the risks and benefits of aspirin use in certain subgroups at risk of both thrombotic and hemorrhagic events is needed.
Wong et al. (Tue,) conducted a case-control in Intracerebral hemorrhage (n=174). Aspirin vs. No aspirin was evaluated on Lobar hematoma location (p=0.002). Aspirin use prior to intracerebral hemorrhage was associated with a significantly higher rate of lobar hematoma compared to nonusers (32.8% vs 10.3%, p=0.002).